Author Archives: Marta Figueiredo PhD

AcuraStem’s AS-202 for ALS Shows Promise in Preclinical Studies

AcuraStem’s experimental therapy AS-202 significantly reduced neurodegeneration and improved motor function and survival in a mouse model of aggressive amyotrophic lateral sclerosis (ALS) associated with toxic clumps of the TDP-43 protein, the company announced. Preclinical studies also confirmed the therapy’s biological activity and target engagement and suggested that…

Pridopidine Arm of HEALEY ALS Platform Trial Fully Enrolled

Prilenia Therapeutics announced the completion of patient enrollment in the pridopidine arm of the HEALEY ALS platform trial, the first study to simultaneously test multiple experimental therapies for amyotrophic lateral sclerosis (ALS). Prilenia’s oral therapy pridopidine was selected as the trial’s fourth regimen (NCT04615923), with…

NurOwn Benefits Patients With Less Severe ALS, Analyses Show

A significantly greater proportion of amyotrophic lateral sclerosis (ALS) patients with less severe disease showed slower ALS progression with the investigational cell-based therapy NurOwn relative to a placebo. These are the findings of another post-hoc analysis of data from NurOwn’s Phase 3 clinical trial (NCT03280056), further supporting the…

Cytokinetics Updates Phase 3 COURAGE-ALS Trial of Reldesemtiv

Most of the initial amyotrophic lateral sclerosis (ALS) patients enrolled in Cytokinetics’ COURAGE-ALS Phase 3 trial testing its experimental therapy reldesemtiv have moderate-to-fast progressing disease at study entry. An analysis shows that, as intended, COURAGE-ALS is increasing the proportion of patients with rapidly progressing disease compared with the…

Oral Edaravone Appears Safe in Patients, Interim Trial Data Show

An oral suspension formulation of edaravone (MT-1186) is safe and well-tolerated in adults with amyotrophic lateral sclerosis (ALS), according to interim, six-month data from a Phase 3 clinical trial. In addition, exploratory efficacy results suggest that edaravone’s experimental oral formulation may slow patients’ functional decline to a similar level…